The role of 68-Ga-DOTATOC CT-PET in surgical tactic for gastric neuroendocrine tumors treatment: our experience: a case report.

[1]  E. Pilozzi,et al.  Gastric carcinoid in the absence of atrophic body gastritis and with low Ki67 index: a clinical challenge , 2014, Scandinavian journal of gastroenterology.

[2]  E. Krenning,et al.  Neuroendocrine tumours: the role of imaging for diagnosis and therapy , 2014, Nature Reviews Endocrinology.

[3]  W. Willinek,et al.  Predictors of Long-Term Outcome in Patients with Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors After Peptide Receptor Radionuclide Therapy with 177Lu-Octreotate , 2014, The Journal of Nuclear Medicine.

[4]  Z. Qian,et al.  Classification, clinicopathologic features and treatment of gastric neuroendocrine tumors. , 2014, World journal of gastroenterology.

[5]  J. Griniatsos,et al.  The validity of current guidelines regarding surgical management of patients with gastric neuroendocrine neoplasms type 1: a report of a series of seven patients , 2013, Hormones.

[6]  M. Berretta,et al.  Giant gastrointestinal stromal tumor (GIST) of the stomach cause of high bowel obstruction: surgical management , 2013, World Journal of Surgical Oncology.

[7]  E. Krenning,et al.  Peptide receptor radionuclide therapy (PRRT) for GEP-NETs. , 2012, Best practice & research. Clinical gastroenterology.

[8]  H. Sasano,et al.  ENETS Consensus Guidelines for the Management of Patients with Gastroduodenal Neoplasms , 2011, Neuroendocrinology.

[9]  M. Malaguarnera,et al.  The neo-adjuvant treatment in gastrointestinal stromal tumor. , 2010, European review for medical and pharmacological sciences.

[10]  M. Malaguarnera,et al.  Elevated chromogranin A (CgA) serum levels in the patients with advanced pancreatic cancer. , 2009, Archives of gerontology and geriatrics.

[11]  I. Drozdov,et al.  Neuroendocrine tumor epidemiology , 2008, Cancer.

[12]  D. Bingham,et al.  Inherited pancreatic endocrine tumor syndromes: Advances in molecular pathogenesis, diagnosis, management, and controversies , 2008, Cancer.

[13]  Manal M. Hassan,et al.  One hundred years after "carcinoid": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Jensen,et al.  A prospective study of gastric carcinoids and enterochromaffin-like cell changes in multiple endocrine neoplasia type 1 and Zollinger-Ellison syndrome: identification of risk factors. , 2008, The Journal of clinical endocrinology and metabolism.

[15]  E. Solcia,et al.  Endocrine hyperplasia and dysplasia in the pathogenesis of gastrointestinal and pancreatic endocrine tumors. , 2007, Gastroenterology clinics of North America.

[16]  G. Klöppel,et al.  Site-specific biology and pathology of gastroenteropancreatic neuroendocrine tumors , 2007, Virchows Archiv.

[17]  A. Runz,et al.  Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours , 2007, European Journal of Nuclear Medicine and Molecular Imaging.

[18]  M. Schubert,et al.  Treatment of gastric carcinoids , 2007, Current treatment options in gastroenterology.

[19]  F. Keleştimur,et al.  Poorly Differentiated Carcinomas of the Foregut (Gastric, Duodenal and Pancreatic) , 2007, Neuroendocrinology.

[20]  B. Kos-Kudła,et al.  Well-Differentiated Gastric Tumors/Carcinomas , 2007, Neuroendocrinology.

[21]  A. Scarpa,et al.  TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system , 2006, Virchows Archiv : an international journal of pathology.

[22]  A. Cavallaro,et al.  La chirurgia nei tumori stromali gastrointestinali CD 117+ (G.I.S.T.) : nostra esperienza , 2006 .

[23]  S. Tamura,et al.  Primary gastric small cell carcinoma: report of a case and review of the literature , 2005, Medical Molecular Morphology.

[24]  H. Scherübl,et al.  Expression of neuroendocrine markers in undifferentiated carcinomas of the gastrointestinal tract. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  I. Modlin,et al.  Current status of gastrointestinal carcinoids. , 2005, Gastroenterology.

[26]  J. Soga.  Early‐stage carcinoids of the gastrointestinal tract , 2005, Cancer.

[27]  J. Norton,et al.  Gastric carcinoid tumors in multiple endocrine neoplasia-1 patients with Zollinger-Ellison syndrome can be symptomatic, demonstrate aggressive growth, and require surgical treatment. , 2004, Surgery.

[28]  I. Modlin,et al.  A 50-Year Analysis of 562 Gastric Carcinoids: Small Tumor or Larger Problem? , 2004, American Journal of Gastroenterology.

[29]  R. Jensen,et al.  Multiple Endocrine Neoplasia Type 1 and Zollinger-Ellison Syndrome: A Prospective Study of 107 Cases and Comparison With 1009 Cases From the Literature , 2004, Medicine.

[30]  P. Schöffski,et al.  Biokinetics and imaging with the somatostatin receptor PET radioligand 68Ga-DOTATOC: preliminary data , 2001, European Journal of Nuclear Medicine.

[31]  L. Gullo,et al.  Treatment of type II gastric carcinoid tumors with somatostatin analogues. , 2000, The New England journal of medicine.

[32]  J. Reubi,et al.  Affinity profiles for human somatostatin receptor subtypes SST1–SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use , 2000, European Journal of Nuclear Medicine.

[33]  M. Stolte,et al.  ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. , 1999, Gastroenterology.

[34]  D. Hoyer,et al.  Classification and nomenclature of somatostatin receptors. , 1995, Trends in pharmacological sciences.

[35]  R. Weller,et al.  International Histological Classification of Tumours , 1981 .

[36]  Fynn Rw.  One hundred years after. , 1959 .

[37]  F. Bösch,et al.  Gastroenteropancreatic Neuroendocrine Tumours , 2019, Gastroenterology For General Surgeons.

[38]  C. Boy,et al.  Differential uptake of (68)Ga-DOTATOC and (68)Ga-DOTATATE in PET/CT of gastroenteropancreatic neuroendocrine tumors. , 2013, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

[39]  M. Berretta,et al.  Clinical and biological markers in gastric cancer: update and perspectives. , 2010, Frontiers in bioscience.

[40]  M. Berretta,et al.  Molecular diagnosis of pancreatic cancer: where do we stand? , 2010, Frontiers in bioscience.

[41]  K. McMasters,et al.  A Proposed Staging System for Gastric Carcinoid Tumors Based on an Analysis of 1,543 Patients , 2008, Annals of Surgical Oncology.

[42]  R. Bale,et al.  Neuroendocrine Tumors: Comparison with Somatostatin Receptor Scintigraphy and CT , 2007 .

[43]  Uwe Haberkorn,et al.  Evaluation of positron emission tomography imaging using [68Ga]-DOTA-D Phe(1)-Tyr(3)-Octreotide in comparison to [111In]-DTPAOC SPECT. First results in patients with neuroendocrine tumors. , 2003, Molecular imaging and biology : MIB : the official publication of the Academy of Molecular Imaging.

[44]  L. Sobin,et al.  Histological Typing of Endocrine Tumours , 2000, International Histological Classification of Tumours.